Serologic and transfusion data of 76 multitransfused patients in the longitudinal study
B19 lgG at baseline/end of study . | . | . | . | . | Lifetime transfusions, no. (%) . | . | |
|---|---|---|---|---|---|---|---|
| . | No. patients . | No. male/no. female . | Mean age, y (range) . | Mean y of follow-up (range) . | Fewer than 100 transfusions* . | More than 100 transfusions† . | |
| Neg/neg | 20 | 10/10 | 12.5 (1-26) | 7.1 (1-18) | 1 (5.3) | 19 (33.3) | |
| Pos/pos | 55 | 22/33 | 32.6 (4-49) | 6.6 (1-16) | 18 (94.7) | 37‡ (64.9) | |
| Neg/pos | 1 | 0/1 | 13 (NA) | 21 (NA) | 0 (0) | 1 (1.8) | |
B19 lgG at baseline/end of study . | . | . | . | . | Lifetime transfusions, no. (%) . | . | |
|---|---|---|---|---|---|---|---|
| . | No. patients . | No. male/no. female . | Mean age, y (range) . | Mean y of follow-up (range) . | Fewer than 100 transfusions* . | More than 100 transfusions† . | |
| Neg/neg | 20 | 10/10 | 12.5 (1-26) | 7.1 (1-18) | 1 (5.3) | 19 (33.3) | |
| Pos/pos | 55 | 22/33 | 32.6 (4-49) | 6.6 (1-16) | 18 (94.7) | 37‡ (64.9) | |
| Neg/pos | 1 | 0/1 | 13 (NA) | 21 (NA) | 0 (0) | 1 (1.8) | |